In a very recent study, Musicant and colleagues demonstrated that the inhibition of PPARγ might be beneficial in mucoepidermoid carcinoma (MEC), a salivary-gland cancer that is driven primarily by a transcriptional coactivator fusion composed of cyclic AMP-regulated transcriptional coactivator 1 (CRTC1) and mastermind-like 2 (MAML2). Here, MAML2 is linked to mucoepidermoid carcinoma.